Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | Advances in EBV-PTLD

Rafael de la Cámara • 24 Sep 2021
IACH 2021
General Lymphoma Antibodies Rituximab

Rafael de la Cámara, MD, Hospital de la Princesa, Madrid, Spain, shares an update on recent advances regarding the treatment of Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD). Whilst the use of pre-emptive therapy with rituximab significantly decreases the EBV-PTLD mortality rate, it is not a suitable treatment option for patients who are rituximab-refractory. Dr Cámara reports that recently adoptive cellular immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTL) has enabled the treatment of these patients. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

More from Rafael de la Cámara

3:04
The optimal time of vaccination for allogeneic stem cell transplant patients
Rafael de la Cámara • 24 Sep 2021

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals